Acquiring Company
Intas Pharmaceuticals Ltd
Acquired Company
Accord BioPharma
Ahmedabad
United StatesManufacturingBiotechnologyHealth CarePharmaceuticalManufacturingDescription
Intas Pharmaceuticals has completed the acquisition of Accord BioPharma, creating one of the largest global suppliers of Pegfilgrastim. This strategic move is aimed at expanding their product offerings in the oncology segment. The merger will enhance their ability to provide high-quality pharmaceutical products worldwide. Both companies aim to leverage their strengths for better healthcare solutions.
Quick answer
Intas Pharmaceuticals Ltd is acquiring Accord BioPharma, announced August 7, 2025. Intas Pharmaceuticals Ltd is based in Ahmedabad, Gujarat, India.
- How much did Intas Pharmaceuticals Ltd pay for Accord BioPharma?
- The deal value was not disclosed.
- What does Intas Pharmaceuticals Ltd do?
- Intas Pharmaceuticals Ltd. is a leading vertically integrated pharmaceutical company based in Ahmedabad, India.
- Where are Intas Pharmaceuticals Ltd and Accord BioPharma based?
- Intas Pharmaceuticals Ltd is based in Ahmedabad, Gujarat, India. Accord BioPharma is based in United States.
- Who are the decision-makers at Intas Pharmaceuticals Ltd?
- Fundz holds 4 contacts at Intas Pharmaceuticals Ltd. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Pharmaceutical and Manufacturing
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Esteve Pharmaceuticals acquires Caprelsa® from Sanofi (July 1, 2025)
- Avanos Medical acquires Nexus Medical for growth (September 15, 2025)
- AbbVie completes acquisition of Capstan Therapeutics (August 19, 2025)
- ESTEVE acquires Regis Technologies for U.S. expansion (July 31, 2025)
- AbbVie to acquire Capstan Therapeutics (July 15, 2025)
- AbbVie to acquire Capstan Therapeutics for $2.1B, $2.1B (June 30, 2025)
Who to call at Intas Pharmaceuticals Ltd, and when
When Intas Pharmaceuticals Ltd changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Intas Pharmaceuticals Ltd raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Intas Pharmaceuticals Ltd, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Intas Pharmaceuticals Ltd. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Intas Pharmaceuticals Ltd makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Accord BioPharma?
Accord BioPharma was acquired by Intas Pharmaceuticals Ltd, based in Ahmedabad. The deal was reported on August 7, 2025. Intas Pharmaceuticals Ltd. is a leading vertically integrated pharmaceutical company based in Ahmedabad, India. Intas Pharmaceuticals Ltd is privately held and operates in Manufacturing.
When did Intas Pharmaceuticals Ltd acquire Accord BioPharma?
Intas Pharmaceuticals Ltd's acquisition of Accord BioPharma was reported on August 7, 2025. Intas Pharmaceuticals has completed the acquisition of Accord BioPharma, creating one of the largest global suppliers of Pegfilgrastim. This strategic move is aimed at expanding their product offerings in the oncology segment. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Accord BioPharma do?
Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, seeks to provide affordable, accessible, patient-centric therapies in oncology, immunology, and critical care. It is privately held, operating in Manufacturing, and is based in United States.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.